Evidence map›Paper›PMID 42234144›Full record

ArticleSurgery today2026

Prognostic stratification of unresectable locally advanced pancreatic cancer using a combination of inflammatory and nutritional indices: a retrospective cohort study.

Michinori Matsumoto, Masashi Tsunematsu, Kenei Furukawa, Koichiro Haruki, Yoshihiro Shirai, Tadashi Uwagawa, Takeshi Gocho, Shinji Onda, Mitsuru Yanagaki, Toru Ikegami

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michinori MatsumotoDepartment of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan. mmatsumoto4@jikei.ac.jp.ORCID http://orcid.org/0000-0002-5860-1103
Masashi TsunematsuDepartment of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Kenei FurukawaDepartment of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Koichiro HarukiDepartment of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Yoshihiro ShiraiDepartment of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Tadashi UwagawaDepartment of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Takeshi GochoDepartment of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Shinji OndaDepartment of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Mitsuru YanagakiDepartment of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Toru IkegamiDepartment of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeResectability in pancreatic cancer (PC) is determined by anatomical, biological, and conditional (ABC) criteria. However, the pretreatment prognostic markers for unresectable locally advanced (UR-LA) PC are insufficient. This study aimed to identify the baseline predictors of survival and establish an inflammation-nutrition-based prognostic score.

methodsThirty-nine patients with UR-LA PC who received chemotherapy or chemoradiotherapy were retrospectively evaluated. Pretreatment biomarkers, including systemic immune-inflammation index (SIII) and body mass index (BMI), were analyzed using Cox proportional hazards models.

resultsMultivariable analysis identified BMI < 18.5 kg/m² (PFS: HR 3.79, p = 0.003; OS: HR 2.88, p = 0.03) and SIII > 900/µL (PFS: HR 3.71, p = 0.002; OS: HR 4.25, p = 0.02) as independent predictors of worse outcomes. High SIII was correlated with elevated neutrophil-to-lymphocyte ratio and lower prognostic nutritional index, whereas low BMI was associated with sarcopenia and reduced feasibility of conversion surgery. A pretreatment SIII/BMI score (0-2 points) effectively stratified survival: median PFS was 16.4, 7.3, and 4.3 months, and median OS was 31.1, 18.0, and 7.1 months for scores 0, 1, and 2, respectively.

conclusionsPretreatment SIII and BMI are strong independent prognostic markers for UR-LA PC. The SIII/BMI score is a practical pretreatment tool aligned with the ABC framework to support individualized treatment planning.

Indexed as

Body Mass IndexInflammationNutritional StatusNutrition AssessmentPancreatic NeoplasmsAgedBiomarkersChemoradiotherapyCohort StudiesFemaleHumansLymphocytesMaleMiddle AgedNeutrophilsPrognosisBiomarkersChemotherapyConversion surgerySystemic-immune-inflammation indexUnresectable locally advanced pancreatic cancer

Identifiers

PMID42234144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.